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Risk prediction models can best be developed in prospec-
tive longitudinal cohort studies, as such studies allow
optimal measurement of predictor and outcome variables
and direct estimation of absolute risk [1]. Prospective
cohort studies may require a large sample size or long
follow-up duration for rare diseases. In contrast, case-
control studies are more efficient, as they require fewer
subjects and can be performed in a shorter timeframe than
prospective cohort studies. However, if not explicitly nes-
ted within a cohort study, case-control studies are generally
deemed less suitable for developing a risk prediction model
due to their inability to allow the calculation of absolute
risk [2].
Karp et al [3] propose an easily applicable method that
allows the calculation of absolute risk in non-nested case-
control studies. They developed a lung cancer risk pre-
diction model based on individuals in the Montreal Lung
Cancer Case-Control study and used population data from
Montreal to weight the controls with age and sex strata
specific study population-time. They present the model
with different time horizons, and flexibility to consider
predictions for various scenarios of risk factor development
over time. We reflect on a number of aspects of the pro-
posed method, in particular with regards to the weighting.
The main issue is the selection process of the cases and
controls. A major limitation of case-control studies,
described as early as 1959, is the difficulty to ensure that
cases and controls are a representative sample of the same
source population [4]. By weighting the controls with age
and sex strata specific study population-time, the assump-
tion that there are no factors influencing the selection of
controls other than those considered in the weighting for-
mula should be carefully considered. The response rates
were allowed to differ by sex (males: 0.862; females
0.818), but not by age or other characteristics than age and
sex. Similarly the proportion of Canadians in Montreal was
set to a constant (0.954), irrespective of other characteris-
tics. Moreover, a complete case ascertainment was
assumed for the Montreal metropolitan area.
The weighting greatly affected the model intercept,
which is expected, as only 1,288 controls were included in
the matched case-control study from over 3 million con-
trols in the Montreal population. Moreover, the odds ratios
changed for age (from 1.1 to 3.4 per decade) and gender
(from 0.7 to 1.2 for male sex). These changes in parameter
estimates are also expected since the weighting is meant to
correct for the age- and sex-matching of cases and controls.
However, the odds ratio for the comprehensive smoking
index (CSI) changed drastically as well: from 10.1 to 31.5.
This illustrates that the weighting can substantially affect
the parameter estimates of risk factors other than the ones
used to match the cases and controls.
Finally, the authors state that the risk-stratifying per-
formance of their method was ‘‘reasonably high’’, based on
assessing the range and variability of 15-year lung cancer
risk across a variety of risk profiles [3]. We note that the
weighting of the control series magnified the differences in
risk profiles between the cases and controls substantially,
as also reflected in an increase in discriminative ability (c
statistic from 0.81 to 0.89). Although the weighted model
apparently estimates a quite diverse range of risks, the key
property for individualized risk information is calibration,
which is again related to the validity of the weighting
procedure. ‘‘Moderate’’ calibration, i.e. the observed event
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rate should be R% among individuals where the model
predicts a risk of R%, has been suggested as the proper
ambition of a proposed model [5]. To assess whether a
model meets this level of calibration, the observed event
rates across different risk profiles are required; i.e., the
absolute risk levels need to be known. As the authors only
used information from a non-nested case control study,
they are unable to assess whether their method correctly
estimates the absolute level of risk of an individual.
We hence agree with the authors that an external vali-
dation study of the weighted model in a population where
the level of absolute risk is known is essential [3]. Such a
study will be valuable in evaluating the validity of the
proposed method to use non-nested case-control studies for
risk model development.
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